12.87USD+2.06%Mkt Cap: 1.08B USDP/E: —Last update: 2026-05-26
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the Un…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.08B USD
Enterprise Value864.02M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.28M USD
Revenue/Share—
Last Price12.87 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS2210151005
Valuation
P/E (Trailing)—
P/E (Forward)-13.82
PEG—
EV/EBITDA-18.07
EV/Revenue—
P/S—
P/B4.57
EPS (TTM)-0.55
EPS (Forward)-0.95
52W Range
3.38040% of range26.95
52W High26.95 USD
52W Low3.380 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-24.97%
ROA-21.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.80M USD
CapEx (TTM)174.00K USD
FCF Margin—
FCF Yield-2.08%
Net Debt-235.88M USD
Net Debt/EBITDA4.93
Balance Sheet
Debt/Equity0.02
Current Ratio19.81
Quick Ratio19.65
Book Value/Sh2.862 USD
Cash/Share2.815 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)33.33 USD
Target Range27.00 USD – 42.00 USD
# Analysts6
Ownership
Shares Out.84.09M
Float72.79M
Insiders3.51%
Institutions85.05%
Short Interest
Short Ratio14.9d
Short % Float24.85%
Short % Out.21.86%
Shares Short18.39M
Short (prev mo.)16.95M
Technical
SMA 5014.83 (-13.2%)
SMA 20011.20 (+15.0%)
Beta0.94
S&P 52W Chg28.31%
Avg Vol (30d)1.67M
Avg Vol (10d)2.26M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—